Kai W Wucherpfennig

USPTO Granted Patents = 20 (Patent Applications = 10)

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 10)

Average Co-Inventor Count = 3.3

ph-index = 5

Forward Citations = 72(Granted Patents)

Location History:

Brookline, MA (US) (1999 - 2023)
Boston, MA (US) (2021 - 2024)

Company Filing History:

18 out of 1,210

Dana-farber-cancer Institute Inc.

patents

4 out of 2,893

The General Hospital Corporation

The Brigham and Women's Hospital, Inc.

patents

5. 2 out of 8,384

Massachusetts Institute of Technology

patents

6. 1 out of 5,309

Leland Stanford Junior University

patents

7. 1 out of 896

The United States Government As Represented by the Department of Veterans Affairs

patents

8. 1 out of 444

The Broad Institute, Inc.

patents

9. 1 out of 1,035

Children's Medical Center Corporation

patents

where one patent can have more than one assignee

Years Active: 1999-2025

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12440451 - Compositions and methods using an epigenetic inhibitor (2025-10-14),

2. 12018080 - Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway (2024-06-25),

3. 11820822 - Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways (2023-11-21),

4. 11597934 - Methods and compositions for reducing immunosuppression by tumor cells (2023-03-07),

5. 11459389 - Monoclonal antibodies that bind human CD161 (2022-10-04),

6. 11421032 - Compositions and methods for inhibition of MICA/B shedding (2022-08-23),

7. 11191823 - Compositions and methods for treating arenavirus infection (2021-12-07),

8. 10993971 - Vaccination with MICA/B alpha 3 domain for the treatment of cancer (2021-05-04),

9. 10876120 - Methods and compositions for reducing immunosupression by tumor cells (2020-12-29),

10. 10793633 - Therapeutic peptides (2020-10-06),

11. 10745483 - Therapeutic peptides (2020-08-18),

12. 10279021 - Vaccine compositions and methods for restoring NKG2D pathway function against cancers (2019-05-07),

13. 10106611 - Antibodies that bind to MHC class I polypeptide-related sequence A (2018-10-23),

14. 9944931 - Methods and compositions for reducing immunosupression by tumor cells (2018-04-17),

15. 9402905 - Therapeutic peptides (2016-08-02),

Title: Kai W Wucherpfennig: Pioneering Cancer Treatment Innovations

Introduction

Kai W Wucherpfennig, based in Brookline, MA, is a distinguished inventor with a significant contribution to the field of cancer research. He holds 19 patents, showcasing his innovative approaches to treating cancer by targeting specific molecular pathways.

Latest Patents

Wucherpfennig's latest patents focus on groundbreaking methods for treating cancer. One such patent involves methods and compositions for targeting the CLEC2D-KLRB1 pathway. This invention outlines ways to treat cancer in subjects by blocking the interaction between the KLRB1 receptor and its ligand, which plays a crucial role in regulating the immune response. Another notable patent presents methods for sensitizing cancer cells to T cell-mediated killing by identifying and modulating cancer biomarkers, thereby enhancing the effectiveness of immunotherapies.

Career Highlights

Throughout his career, Wucherpfennig has made significant strides in cancer research. His work at the Dana-Farber Cancer Institute and The General Hospital Corporation has contributed greatly to the understanding of immune evasion in tumors and therapeutic interventions for cancer treatment.

Collaborations

Wucherpfennig has collaborated with esteemed colleagues in the field, including Glenn Dranoff and F. Stephen Hodi. These partnerships have fostered innovative approaches to cancer therapy and have driven advancements in immuno-oncology.

Conclusion

Kai W Wucherpfennig stands out as a noteworthy inventor in cancer research, with his patents reflecting a commitment to improving treatment methodologies. His work continues to pave the way for significant advancements in cancer treatment, highlighting the importance of targeted therapies and collaboration in the scientific community.

This text is generated by artificial intelligence and may not be accurate.